Vestcor Inc Sells 416 Shares of Insulet Co. (NASDAQ:PODD)

Vestcor Inc decreased its stake in shares of Insulet Co. (NASDAQ:PODD) by 26.0% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 1,187 shares of the medical instruments supplier’s stock after selling 416 shares during the period. Vestcor Inc’s holdings in Insulet were worth $310,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. SBI Securities Co. Ltd. bought a new position in shares of Insulet in the fourth quarter valued at approximately $36,000. SRS Capital Advisors Inc. increased its holdings in Insulet by 43.1% during the 4th quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier’s stock worth $49,000 after acquiring an additional 56 shares during the period. TD Private Client Wealth LLC boosted its holdings in Insulet by 32.6% in the 3rd quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier’s stock valued at $53,000 after purchasing an additional 56 shares during the period. Friedenthal Financial purchased a new position in shares of Insulet during the 4th quarter valued at $57,000. Finally, Assetmark Inc. increased its holdings in shares of Insulet by 1,447.1% in the fourth quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier’s stock worth $69,000 after purchasing an additional 246 shares during the period.

Insulet Stock Performance

Shares of PODD stock opened at $261.63 on Tuesday. The company has a market capitalization of $18.37 billion, a P/E ratio of 45.19, a PEG ratio of 3.62 and a beta of 1.29. Insulet Co. has a fifty-two week low of $160.19 and a fifty-two week high of $289.46. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. The stock has a 50 day moving average price of $272.40 and a two-hundred day moving average price of $255.72.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 EPS for the quarter, beating analysts’ consensus estimates of $1.00 by $0.15. The company had revenue of $597.50 million during the quarter, compared to analyst estimates of $582.02 million. Insulet had a net margin of 20.19% and a return on equity of 24.46%. Analysts expect that Insulet Co. will post 3.92 earnings per share for the current year.

Insider Transactions at Insulet

In other Insulet news, EVP Eric Benjamin sold 12,394 shares of the stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total value of $3,470,320.00. Following the completion of the sale, the executive vice president now owns 11,383 shares in the company, valued at approximately $3,187,240. This trade represents a 52.13 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.47% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several equities research analysts recently issued reports on PODD shares. JPMorgan Chase & Co. lifted their price objective on Insulet from $280.00 to $330.00 and gave the company an “overweight” rating in a research note on Thursday, December 12th. Canaccord Genuity Group boosted their price objective on Insulet from $304.00 to $324.00 and gave the stock a “buy” rating in a report on Friday, February 21st. Wells Fargo & Company raised their target price on shares of Insulet from $305.00 to $322.00 and gave the company an “overweight” rating in a research note on Friday, February 21st. Raymond James reissued an “outperform” rating and issued a $328.00 price target (up previously from $294.00) on shares of Insulet in a research note on Friday, February 21st. Finally, TD Cowen raised their price objective on shares of Insulet from $264.00 to $324.00 and gave the company a “buy” rating in a research report on Friday, January 3rd. Four equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $292.06.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.